Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
166 hedge funds and large institutions have $1.05B invested in Momenta Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 68 increasing their positions, 44 reducing their positions, and 18 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 44
45% more call options, than puts
Call options by funds: $3.76M | Put options by funds: $2.59M
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
5% more funds holding
Funds holding: 158 → 166 (+8)
23% less capital invested
Capital invested by funds: $1.36B → $1.05B (-$308M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.7M |
| 2 |
Millennium Management
New York
|
+$10.4M |
| 3 |
TAM
Tocqueville Asset Management
New York
|
+$9.24M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$13.3M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.25M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$8.4M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$6.91M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$6.37M |
MNTA Hedge Fund Activity: Q4 2017 in Review
166 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2017, worth a combined $1.05B — down 23% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MNTA positions and 18 closed out — a net gain of 8 holders — while 68 added to existing stakes and 44 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $20.7M. The largest seller was OrbiMed, cutting an estimated $13.3M.
- 166 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2017, up from 158 in Q3 2017.
- Funds reported $1.05B of Momenta Pharmaceuticals, Inc. stock for Q4 2017, down 23% quarter-over-quarter.
- 26 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2017 and 18 closed out, a net change of +8 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $20.7M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q4 2017 was OrbiMed, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2017.